
Hunan Fangsheng Pharmaceutical Co., Ltd.
SSE:603998.SS
10.78 (CNY) • At close June 10, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 1,777.494 | 1,628.542 | 1,792.001 | 1,566.973 | 1,278.765 | 1,093.754 | 1,051.077 | 720.769 | 534.257 | 468.559 | 415.613 | 400.262 | 332.305 | 262.675 |
Cost of Revenue
| 500.368 | 519.538 | 586.285 | 563.272 | 463.709 | 299.565 | 272.919 | 288.499 | 271.087 | 206.078 | 217.551 | 234.522 | 183.668 | 153.273 |
Gross Profit
| 1,277.126 | 1,109.004 | 1,205.716 | 1,003.701 | 815.056 | 794.189 | 778.158 | 432.27 | 263.17 | 262.481 | 198.062 | 165.739 | 148.638 | 109.402 |
Gross Profit Ratio
| 0.718 | 0.681 | 0.673 | 0.641 | 0.637 | 0.726 | 0.74 | 0.6 | 0.493 | 0.56 | 0.477 | 0.414 | 0.447 | 0.416 |
Reseach & Development Expenses
| 139.214 | 107.926 | 70.396 | 51.4 | 53.616 | 41.233 | 42.348 | 20.944 | 12.854 | 15.66 | 12.277 | 10.634 | 11.725 | 9.709 |
General & Administrative Expenses
| 32.203 | 146.411 | 41.033 | 29.254 | 31.842 | 21.111 | 15.762 | 18.37 | 17.923 | 18.139 | 13.036 | 9.241 | 9.785 | 6.447 |
Selling & Marketing Expenses
| 600.378 | 657.685 | 755.249 | 633.488 | 484.19 | 541.813 | 534.264 | 223.112 | 79.113 | 69.409 | 37.279 | 27.077 | 26.427 | 14.109 |
SG&A
| 632.581 | 805.792 | 796.282 | 662.741 | 516.032 | 562.924 | 550.026 | 241.482 | 97.036 | 87.548 | 50.315 | 36.319 | 36.212 | 20.556 |
Other Expenses
| 219.987 | -0.376 | 128.572 | 146.071 | 123.151 | 88.564 | 0.104 | 0.156 | 4.899 | 6.492 | 6.089 | 3.858 | 2.719 | 2.777 |
Operating Expenses
| 991.782 | 912.558 | 995.25 | 860.213 | 692.798 | 692.721 | 669.257 | 339.03 | 181.048 | 160.399 | 103.514 | 80.092 | 73.428 | 50.707 |
Operating Income
| 285.344 | 196.446 | 332.039 | 99.694 | 103.238 | 96.361 | 92.083 | 80.207 | 83.989 | 108.887 | 95.001 | 84.978 | 75.754 | 59.371 |
Operating Income Ratio
| 0.161 | 0.121 | 0.185 | 0.064 | 0.081 | 0.088 | 0.088 | 0.111 | 0.157 | 0.232 | 0.229 | 0.212 | 0.228 | 0.226 |
Total Other Income Expenses Net
| 0.643 | 6.893 | -5.465 | -8.903 | -34.266 | -1.885 | 0.104 | 0.156 | 4.438 | 5.824 | 5.854 | 3.844 | 2.591 | 2.763 |
Income Before Tax
| 285.988 | 203.338 | 326.575 | 90.791 | 68.972 | 94.475 | 92.187 | 80.363 | 88.623 | 114.71 | 100.855 | 88.822 | 78.345 | 62.133 |
Income Before Tax Ratio
| 0.161 | 0.125 | 0.182 | 0.058 | 0.054 | 0.086 | 0.088 | 0.111 | 0.166 | 0.245 | 0.243 | 0.222 | 0.236 | 0.237 |
Income Tax Expense
| 36.139 | 23.714 | 49.873 | 20.87 | 15.195 | 15.501 | 12.38 | 15.739 | 15.188 | 17.799 | 14.981 | 13.205 | 11.325 | 10.528 |
Net Income
| 255.216 | 186.823 | 285.853 | 70.041 | 63.794 | 78.911 | 72.994 | 59.68 | 69.756 | 90.676 | 80.993 | 73.435 | 66.114 | 51.876 |
Net Income Ratio
| 0.144 | 0.115 | 0.16 | 0.045 | 0.05 | 0.072 | 0.069 | 0.083 | 0.131 | 0.194 | 0.195 | 0.183 | 0.199 | 0.197 |
EPS
| 0.59 | 0.43 | 0.67 | 0.16 | 0.15 | 0.19 | 0.17 | 0.14 | 0.16 | 0.21 | 0.32 | 0.23 | 0.21 | 0.16 |
EPS Diluted
| 0.58 | 0.42 | 0.67 | 0.16 | 0.15 | 0.18 | 0.17 | 0.14 | 0.16 | 0.21 | 0.32 | 0.23 | 0.21 | 0.16 |
EBITDA
| 384.026 | 310.089 | 444.313 | 187.541 | 156.254 | 170.687 | 141.756 | 122.143 | 121.1 | 121.893 | 111.487 | 99.265 | 89.84 | 73.079 |
EBITDA Ratio
| 0.216 | 0.19 | 0.248 | 0.12 | 0.122 | 0.156 | 0.135 | 0.169 | 0.227 | 0.26 | 0.268 | 0.248 | 0.27 | 0.278 |